[Form 4] Channel Therapeutics Corporation Insider Trading Activity

Rhea-AI Filing Summary

Pelthos Therapeutics Inc. (PTHS) Form 4 filing: Chief Financial Officer, Treasurer & Secretary Francis Knuettel II reported equity awards granted on 07/02/2025.

• Restricted Stock Units (RSUs): 33,472 underlying common shares at an exercise price of $13.50. One-third vests on 07/02/2026; the remainder vests quarterly over the next two years.
• Stock Options: 102,000 options with a $13.50 strike, identical vesting schedule. Total derivative securities now beneficially owned: 145,074 options.
• Reverse Split Adjustment: Share amounts reflect the 1-for-10 reverse split completed on 07/01/2025.
• Ownership Form: All securities are held directly by the reporting officer.

No sales or dispositions occurred; the filing records routine incentive grants that align the CFO’s compensation with future share performance.

Positive

• Alignment of interests: Multi-year vesting links CFO compensation to long-term share performance.

Negative

• Potential dilution: 135,472 additional shares could enter the float as awards vest and options are exercised.

Insights

Equity Compensation Analyst

TL;DR: Routine grant of 33,472 RSUs and 102,000 options to CFO; modest dilution, little immediate market impact.

The filing discloses standard long-term incentive awards that follow a three-year vesting schedule, encouraging retention and performance alignment. The $13.50 exercise price equals the reference price on grant date, indicating at-the-money options rather than discounted awards. Combined with the 1-for-10 reverse split, absolute share counts are relatively low, limiting dilution. Because no shares were sold and the amounts appear immaterial relative to typical public-company float, the event is unlikely to influence near-term valuation.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Francis Knuettel II

(Last) (First) (Middle)

C/O PELTHOS THERAPEUTICS INC.

4020 STIRRUP CREEK DRIVE, SUITE 110

(Street)

DURHAM NC 27703

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Pelthos Therapeutics Inc. [ PTHS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CFO, Treas & Secty

3. Date of Earliest Transaction (Month/Day/Year)
07/02/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	$13.5	07/02/2025		A		33,472		07/02/2026(1)	07/02/2035	Common Stock	33,472	(1)	33,472	D
Stock Option	$13.5	07/02/2025		A		102,000		07/02/2026(2)	07/02/2035	Common Stock	102,000	(2)	145,074(3)	D

Explanation of Responses:

1. On July 2, 2025, the Reporting Person was granted restricted stock units to purchase 33,472 shares of common stock at an exercise price of $13.50 per share, with the initial one third (1/3) of such shares vesting on July 2, 2026, and in equal installments on a quarterly basis thereafter over a period of two (2) years.

2. On July 2, 2025, the Reporting Person was granted stock options to purchase 102,000 shares of common stock at an exercise price of $13.50 per share, with the initial one third (1/3) of such shares vesting on July 2, 2026, and quarterly thereafter in equal installments over a period of two (2) years.

3. The numbers reported herein have been adjusted to reflect the 1-for-10 reverse stock split effected by the Issuer on July 1, 2025.

	/s/ Francis Knuettel II	07/07/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What equity awards did PTHS grant to its CFO on July 2, 2025?

The company granted 33,472 RSUs and 102,000 stock options at a $13.50 exercise price.

When will the new PTHS equity awards vest?

One-third of each award vests on 07/02/2026; the remainder vests quarterly over the subsequent two years.

Do the reported figures reflect Pelthos Therapeutics’ reverse stock split?

Yes, all share numbers are adjusted for the 1-for-10 reverse split completed on 07/01/2025.

How many derivative securities does the CFO own after this grant?

Following the grant, he beneficially owns 145,074 stock options directly.

Was any stock sold by the executive in this filing?

No. The Form 4 only records awards granted; no shares were sold or disposed of.